Similar Survival on Automated Peritoneal Dialysis and Continuous Ambulatory Peritoneal Dialysis in a Large Prospective Cohort
|
|
- Lesley Morgan
- 5 years ago
- Views:
Transcription
1 Similar Survival on Automated Peritoneal Dialysis and Continuous Ambulatory Peritoneal Dialysis in a Large Prospective Cohort Wieneke Marleen Michels,* Marion Verduijn, Elisabeth Wilhelmina Boeschoten, Friedo Wilhelm Dekker, and Raymond Theodorus Krediet,* for the NECOSAD Study Group *Division of Nephrology, Department of Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands; Hans Mak Institute, Naarden, the Netherlands Background and objectives: Automated peritoneal dialysis (APD) is increasingly used in comparison with continuous ambulatory peritoneal dialysis (CAPD). Although APD is expected to improve survival, convincing evidence of major advantages is lacking. The objective was to investigate whether overall mortality and technique failure of incident dialysis patients treated with APD are different from those treated with CAPD. Design, setting, participants, & measurements: Patients on APD or CAPD at 3 mo after start of dialysis were selected from a prospective multicenter cohort study in incident dialysis patients (NECOSAD). Overall mortality was studied with an intention-to-treat design; the event was death. Technique failure was studied with an as-treated design; the event was a switch of dialysis modality. Hazard ratios (HRs) were calculated with a follow-up of 5 yr. The HRs were adjusted for gender, age, primary kidney disease, comorbidity, residual GFR, urine production and plasma albumin at 3 mo after inclusion. Results: Eighty-seven APD and 562 CAPD patients were included. In the intention-to-treat analysis 154 CAPD and 21 APD patients died. The crude HR for overall mortality was 0.98 (95% CI: ), the adjusted HR was In the as-treated analysis 238 CAPD and 34 APD patients switched therapy, whereas 91 CAPD and 7 APD patients died. The crude HR for technique failure was 0.92 (95% CI: ) and did not change after adjustment. Conclusions: No difference was found in overall mortality and technique failure for APD compared with CAPD in incident dialysis patients. Clin J Am Soc Nephrol 4: , doi: /CJN Automated peritoneal dialysis (APD) is increasingly used in comparison with continuous ambulatory peritoneal dialysis (CAPD). Although APD has been expected to improve survival, convincing evidence of major advantages is lacking. In addition APD has potential disadvantages compared with CAPD like a possible faster decline in residual renal function (1 3), less sodium removal (3 6) and more peritoneal protein loss (6). Furthermore, APD is more expensive than CAPD. Two observational studies reported better overall and technique survival on APD (7,8). However, other studies could not demonstrate a benefit for APD in terms of survival (5,9). Three randomized controlled trials comparing APD to CAPD have been published (10 12). The number of patients was relatively small: the largest study comprised 50 patients Received September 3, Accepted January 12, Published online ahead of print. Publication date available at Correspondence: Wieneke Michels, MD, Academical Medical Center, Division of Nephrology, A01 132, PO BOX 22660, 1100 DD Amsterdam, the Netherlands. Phone: ; Fax: , w.m.michels@amc.uva.nl in the largest group (11). These were reviewed in 2006 (13,14), and no significant differences in survival were found. Comparison of the published studies about this subject is complicated because the indications for APD differ between countries and nephrologists. At the same time, the uncertainty in the literature about the expected benefit of APD probably contributes to these differences in indications. The comparison is also complicated by the different patient selections in the studies; some included prevalent and incident APD patients (9), others included incident patients for PD (7,8) or incident dialysis patients (5,9). The definition of APD differs between the studies as well. Large prospective observational cohorts in incident dialysis patients are required to gain more insight into survival on APD compared with CAPD. The Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) is a large prospective, multicenter cohort study of end-stage renal disease (ESRD) patients starting on dialysis treatment. We used the NECOSAD database to investigate whether overall mortality and technique failure of incident dialysis patients treated with APD are different from those of patients treated with CAPD. Copyright 2009 by the American Society of Nephrology ISSN: /
2 944 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 4: , 2009 Patients and Methods Patients NECOSAD is a prospective multicenter cohort study in which incident adult ESRD patients were included between 1997 and Thirtyeight dialysis centers in the Netherlands participated in the study. Patients preference was the main reason to start APD. The patients were monitored from the start of dialysis, at 3 mo, and thereafter at 6-mo intervals until kidney transplantation or death. All invited patients gave informed consent before inclusion, and the committees of medical ethics of all participating centers approved the study. In the present analysis, all patients treated with APD or CAPD at 3 mo after the start of dialysis (baseline) were included. This time point was chosen because patients switch to another therapy or deaths within this period were most probably due to their health status before the start of dialysis, rather than the dialysis modality. Data Collection Procedures At the start of dialysis treatment the following data were collected: age, sex, primary kidney disease, residual renal function (residual GFR, renal Kt/V urea, urine production), and comorbidity. Residual renal function was expressed as the residual GFR (rgfr), which was calculated as the mean of creatinine and urea clearance adjusted for body surface area (ml/min/1.73 m 2 ). Urea and creatinine levels were measured in plasma and urine samples. The comorbidity was scored on the basis of the number of comorbid conditions according to the comorbidity index described by Davies et al. (15). The patients were classified as having no, intermediate, or severe comorbidity. Primary kidney disease was classified according to the codes of the European Renal Association European Dialysis and Transplant Association (16). At the start, data on social parameters were also collected. These included marital stage, the possession of children (and if so, how many), unpaid and paid work, and education level. The presence of a sleep disorder was defined as the regular use of sleep medication. Data on biochemistry, nutritional status, and dialysis parameters were collected at the 3-mo visit and every 6 mo from the start of dialysis. The Subjective Global Assessment (SGA) scale was used to score the nutritional status. This is a standardized 7-point scale based on the clinical judgment of a dialysis nurse (17). Malnutrition was defined as an SGA-score of 5 or less. Analysis Numbers are presented as means and SD for continuous variables, and as numbers with valid percentages for categorical variables. For continuous variables differences were tested with t test; the 2 was used for categorical variables. The Fisher exact test was used in case the variables did not meet the criteria for the 2 test. A P value 0.05 was considered significant. All statistical analyses were performed in SPSS for windows 14.0 (SPSS Inc, Chicago, IL). Incidence rates were calculated for overall mortality and technique failure. With the Cox proportion hazards model, hazard ratios (HRs) and the associated 95% confidence intervals (CIs) were calculated for APD patients compared with CAPD patients. Patients survival time was calculated from baseline. Moreover, HRs were adjusted for age, gender, primary kidney disease, comorbidity, rgfr, urine production and plasma albumin at baseline. These variables are all known predictors of survival on dialysis. Two main analyses were performed: an intention-to-treat and an as-treated analysis. The intention-to-treat analysis was used to study overall mortality. The event was death; patients were censored for all other reasons of drop-out, at withdrawal or at August 20, Maximum follow-up was 5 yr from the start of dialysis. In this analysis modality switches were ignored, and deaths were ascribed to the primary treatment modality at baseline. To study technique failure, an as-treated design was used. The event was modality change: either to hemodialysis (HD) or to another form of peritoneal dialysis (PD); censoring was applied for death, other reasons of dropout, at withdrawal, or at August Thus, patients were followed from their original PD modality until their first switch to any other form of dialysis (CAPD, APD, or HD) or censoring. Patients were censored at 3 mo after the last date with available information on PD modality, when the date of withdrawal was more then 6 mo afterwards. Maximum follow-up was 5 yr from start of dialysis. Temporarily switches to HD were ignored if shorter than 3 mo. Overall mortality was also studied with an as-treated design. Contrary to the technique survival, in this analysis, the event was death on the original treatment modality, and patients were censored at the time of modality change for all other reasons of drop-out, at withdrawal, or at August 20, If patients died within 3 mo after the switch to another dialysis modality, this switch was ignored and the death was allocated to the primary dialysis modality. The remainder of the analysis was identical to the technique failure analysis. Stratification was used to analyze differences in overall mortality and technique failure for younger (up to 60 yr) and elderly patients. Stay on original PD modality was analyzed in the as-treated design, with technique failure and mortality as a combined end-point. A conditional survival analysis was performed to study the longterm effect of PD modality on overall mortality and technique failure (18). First, the influence of PD modality on survival in the first 2 yr was calculated to study the short term effect. Second, we calculated the influence of PD modality at baseline on the period from 2 to 5 yr from baseline, conditionally on having survived the first 2 yr of dialysis. Thus, patients selected for the conditional analysis were those without an event in the first 2 yr. For the conditional technique failure analysis patients who stayed the first 2 yr on the same PD modality were selected. The effect of APD compared with CAPD on survival might be different for patients who use these therapies at 1 yr after the start of dialysis. To analyze these differences, we performed an additional analysis on overall mortality. In this analysis, we included all patients treated with APD or CAPD, 1 yr after inclusion in NECOSAD. These patients were followed until death or other reasons of drop-out according to the overall mortality analysis previously described, with a maximum follow-up of 5 yr. The variables at baseline (3 mo) were used for adjustment for confounders. Results At baseline, 562 patients who were treated with CAPD and 87 patients who were treated with APD were included. The physical characteristics of these patients are presented in Table 1; their social characteristics are presented in Table 2. No major differences were present at baseline between the CAPD and the APD patients. The adjusted analyses could be performed in 617 of the 649 included patients. Mortality Analyses In the intention-to-treat analysis, 154 CAPD (27%) and 21 APD (24%) patients died. Myocardial ischemia and infarction were the most frequent causes of death in the group with a known cause. The causes of death are listed in Table 3.
3 Clin J Am Soc Nephrol 4: , 2009 Similar Survival in APD and CAPD 945 Table 1. Baseline characteristics Variable CAPD (n 562) APD (n 87) P Gender (male) 370 (65.8%) 68 (78.2%) 0.02 Age (yrs) 53.4 (14.5) 51.5 (16.3) 0.32 Systolic blood pressure (mmhg) (21.1) (21.2) 0.49 Diastolic blood pressure (mmhg) 84.5 (12.1) 83.6 (11.5) 0.49 Residual GFR (ml/min/1.73 m 2 ) 4.4 (3.4) 4.3 (3.0) 0.79 Urine production (l/24 h) 1.2 (0.8) 1.0 (0.7) 0.01 Primary kidney disease diabetes mellitus 85 (15.2%) 15 (17.4%) 0.14 glomerulonephritis 110 (19.6%) 13 (15.1%) renal vascular disease 73 (13.0%) 5 (5.8%) other 293 (52.2%) 53 (61.6%) SGA score 5 89 (17.6%) 11 (19.3%) (35.9%) 17 (29.8%) (46.5%) 29 (50.9%) Davies score no comorbidity 324 (57.7%) 61 (70.1%) 0.09 intermediate comorbidity 199 (35.4%) 22 (25.3%) high comorbidity 39 (6.9%) 4 (4.6%) Hemoglobin (g/dl) 11.8 (1.6) 11.8 (1.4) 0.84 Albumin (g/dl) 3.6 (0.5) 3.7 (0.5) 0.11 Age, residual GFR (glomerular filtration rate), urine production, blood pressure, albumin and hemoglobin, are expressed as mean values (standard deviation). Gender, primary kidney disease and SGA (Subjective Global Assessment scale) are expressed as numbers (valid percentages). Davies scores are expressed as numbers (percentages). GFR, glomerular filtration rate; SGA score, Standard Global Assessment score, higher scores indicate better nutritional status (7, well nourished; 6, nourished; 5 malnourished). Ninety CAPD patients (16%) completed the follow-up of 5 yr compared with 12 APD patients (14%). Reasons for censoring in the CAPD group were transplantation for 204 patients (36%) and recovery of kidney function in three patients (1%). In the APD group, 29 patients (33%) were censored because of transplantation, and two (2%) because of recovery. The incidence rate of death was 110 per 1000 person-years on CAPD, and 106 per 1000 person-years on APD. Figure 1 shows the Kaplan-Meier curves for overall mortality in CAPD and APD patients. The crude HR of APD compared with CAPD for overall mortality was 0.98 (95% CI: 0.62 to 1.54). After adjustment for the previously mentioned variables, the HR was 1.09 (95% CI: 0.65 to 1.83). Adjustment for social factors or potential dialysis center effects in addition to the other confounders did not change the HRs. After stratification for age, the group with younger patients consisted of 370 CAPD and 57 APD patients. In the group aged 60 yr, 57 patients started on CAPD and 30 on APD. The HRs were similar for both groups of age and did not change after adjustment. These results are summarized in Table 4. When we analyzed overall mortality with the as-treated design as described in Patients and Methods, the incidence rate was 106 per 1000 person-years on CAPD and 54 per 1000 person-years on APD. The crude HR was 0.51 (95% CI: 0.24 to 1.11); after adjustment the HR was 0.75 (95% CI: 0.30 to 1.89). Technique Failure In the as-treated analysis, 238 CAPD patients (42%) switched therapy, compared with 34 (39%) in the APD group. Of these, 103 CAPD (18%) and 22 APD (25%) patients switched to HD, whereas 135 CAPD (24%) patients switched to APD and 12 APD patients (14%) made the switch to CAPD. During followup, 91 CAPD (16%) patients died, compared with seven APD patients (8%). The follow-up was completed by 28 CAPD patients (5%) and 3 APD patients (3%). One hundred four CAPD patients (18%) and 21 APD patients (24%) were censored for transplantation. Three CAPD patients (1%) were censored because of recovery of renal function. No patients recovered in the APD group. The incidence rate of technique failure was 279 per 1000 person-years on CAPD and 263 per 1000 person-years on APD. Figure 1 shows the Kaplan-Meier curves for technique failure in CAPD and APD patients. The crude HR of APD compared with CAPD for technique failure was 0.92 (95% CI: 0.64 to 1.31). After adjustment, the HR was 0.91 (95% CI: 0.63 to 1.32). Adjustment for social factors or potential dialysis center effects on top of the other confounders did not change the HRs.
4 946 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 4: , 2009 Table 2. Social characteristics at baseline Variable CAPD (n 562) APD (n 87) P Married/living with partner 417 (77.4%) 56 (71.8%) 0.28 Marital state married 417 (77.4%) 56 (71.8%) 0.54 divorced 42 (7.8%) 7 (9.0%) widow 25 (4.6%) 3 (3.4%) never married 55 (10.2%) 12 (15.4%) Day job (not paid) Retired 154 (38.6%) 25 (46.3%) 0.09 Student 12 (3.0%) 5 (9.3%) Unemployed 23 (5.8%) 2 (3.7 5) Medically incapable of work because of kidney 97 (17.3%) 13 (24.1%) disease Medically incapable of work because of other 51 (12.8%) 6 (11.1%) reason Household and / or children 62 (15.5%) 3 (5.6%) Day job (paid) 176 (32.8%) 29 (33.3%) 0.41 Education low 259 (48.1%) 28 (36.4%) 0.05 high 280 (51.9%) 49 (63.6%) Children 404 (74.7%) 53 (68.8%) 0.27 Number of children 1.9 (1.7) 1.5 (1.2) 0.05 Sleep problem 67 (13%) 5 (7%) 0.17 Hours of paid work and number of children are expressed as mean values (standard deviation). Married / living with partner, day job (not paid), day job (paid), education, children and sleep problems are expressed as numbers (valid percentages). Low education level defined as primary school, lower vocational training; high education level defined as lower general secondary education, pre-university education, high vocational training, or university. Table 3. Causes of death in the overall mortality analysis Cause CAPD APD Myocardial ischemia and infarction 26 (17%) 7 (33%) Heart failure 13 (8%) 0 (0%) Cerebrovascular accident 10 (6%) 1 (5%) Infection 22 (14%) 3 (14%) Discontinuation treatment 22 (14%) 3 (14%) Malignancies 14 (9%) 0 (0%) Unknown / unavailable 48 (31%) 7 (33%) Total Causes of death in the patients studied for overall mortality with an intention-to-treat design. Stratification for age provided a crude HR of 0.69 (95% CI: 0.43 to 1.10) for technique failure in patients up to 60 yr of age. After adjustment the HR did not change. The crude HR for technique failure in the elderly group was 1.77 (95% CI: 0.99 to 3.14). After adjustment the HR was 1.63 (95% CI: 0.87 to 3.05). The HRs are summarized in Table 4. Stay on Original PD Modality To assess whether the time on original PD was different between APD and CAPD, we combined overall mortality and technique survival in the as-treated design. The events were death or switch to another form of dialysis and death; drop-out for all other reasons was censored. For duration on original PD modality, the crude HR was 0.81 (95% CI: 0.58 to 1.12). The adjusted HR was 0.86 (95% CI: 0.61 to 1.22). Conditional Analysis In this analysis the first 2 yr were compared with the last 3 yr of follow-up. During the first 2 yr, 84 CAPD (15%) and 10 APD (11%) patients died in the intention-to-treat analysis. The crude HR for overall mortality was 0.80 (CI 95%: 0.41 to1.53) for the first 2 yr. After adjustment the HR was 0.98 (95% CI: 0.44 to
5 Clin J Am Soc Nephrol 4: , 2009 Similar Survival in APD and CAPD 947 Figure 1. Left: Kaplan-Meier curve of overall mortality on automated peritoneal dialysis compared with continuous ambulatory peritoneal dialysis. Right: Kaplan-Meier curve of pure technique failure on automated peritoneal dialysis compared with continuous ambulatory peritoneal dialysis. The numbers under the graphs show the number of patients at risk. Table 4. Hazard ratios Group Overall mortality Technique failure Complete group crude 0.98 (0.62 to 1.54) 0.92 (0.64 to 1.31) adjusted 1.09 (0.65 to 1.83) 0.91 (0.63 to 1.32) Age 60 yr crude 1.08 (0.53 to 2.18) 0.69 (0.43 to 1.10) adjusted 1.34 (0.60 to 2.98) 0.69 (0.43 to 1.11) Age 60 yr crude 1.04 (0.57 to 1.89) 1.77 (0.99 to 3.14) adjusted 0.95 (0.46 to 1.97) 1.63 (0.87 to 3.05) Analysis 0 to 2 yr crude 0.80 (0.41 to 1.53) 0.91 (0.61 to 1.35) adjusted 0.98 (0.44 to 2.17) 0.93 (0.62 to 1.39) Conditional analysis 2 to 5 yr crude 1.23 (0.65 to 2.32) 0.96 (0.41 to 2.25) adjusted 1.22 (0.61 to 2.41) 1.00 (0.38 to 2.65) Hazard ratios and the associated 95% confidence intervals for overall mortality and technique failure on automated peritoneal dialysis compared with continuous ambulatory peritoneal dialysis. Adjustment was performed for age, gender, primary kidney disease, comorbidity, residual glomerular filtration rate, urine production, and plasma albumin at baseline. 2.17). To calculate the HR for the long-term effect, 332 patients who initially started on CAPD and 44 patients who started on APD were included. Seventy CAPD patients and 11 APD patients died during the last 3 yr. The crude HR of mortality for this period was 1.23 (95% CI: 0.65 to 2.32); after adjustment, the HR was 1.22 (95% CI: 0.61 to 2.41). In the as-treated analysis for technique failure, 193 (34%) CAPD patients and 28 (32%) APD patients switched therapy during the first 2 yr. The crude HR for technique failure was 0.91 (95% CI: 0.61 to 1.35) during this period, after adjustment the HR was 0.93 (95% CI: 0.62 to 1.39). In the conditional analysis for the long-term effect, 185 CAPD and 24 APD patients were included. Forty-five patients switched therapy in the CAPD group compared with 6 patients in the APD group during the last 3 yr. For this period the crude HR for technique failure was 0.96 (95% CI: 0.41 to 2.25), the adjusted HR was 1.00 (95% CI: 0.38 to 2.65). Comparison at 1 Yr After Start of Dialysis One year after inclusion in NECOSAD, 375 patients used CAPD as renal replacement therapy compared with 138 APD patients. In this additional analysis, the APD group contained more men than the CAPD group (74% versus 65%). Furthermore, the patients on APD group had a higher plasma albumin compared with the CAPD patients; median 38.0 (range, 24.0 to 49.0) versus 36.0 g/l (range, 24.0 to 49.0). The other physical parameters were not different. During follow-up, 108 (29%) CAPD patients and 28 (20%) APD patients died. The crude HR for overall survival on APD compared with CAPD was 0.73 (95% CI: 0.48 to 1.10). The adjusted HR was 0.82 (95% CI: 0.51 to 1.32). Discussion This study showed no difference in overall mortality and technique failure for patients treated with APD compared with
6 948 Clinical Journal of the American Society of Nephrology Clin J Am Soc Nephrol 4: , 2009 those treated with CAPD. Moreover, no short-term or longterm effect of PD modality on overall mortality or technique failure was found. Neither was there an effect of PD modality on overall mortality or technique failure in patients who were on one of these treatments 1 yr after the start of dialysis. Stratification for age did not change the results significantly, although the point estimates for technique failure in the younger groups were lower than those in the older group. This indicates that younger patients remain on APD longer, whereas older patients remain on CAPD longer. Furthermore, we observed that the majority of patients who failed on APD switched to HD, whereas patients who failed on CAPD switched to APD. An explanation for the low point estimate in the younger group could be that these patient and their physicians were more motivated to keep them on APD to avoid HD. In older patients, APD can be less favorable because of a higher prevalence of comorbidities, which can make it difficult to handle the machine. Therefore, it can be hypothesized that these patients and their physicians try to keep CAPD as their dialysis modality. Several potential sources of bias and confounding exist for this observational study. The comparison of two therapies in an observational design makes confounding by indication the most important obstacle. However, at baseline, no major differences in medical or social characteristics were present between the CAPD and APD patients. Only urine production was significantly different when tested, although we do not consider a mean difference of 200 ml/24 h clinically important. Because several small differences together might introduce a difference between the groups, we corrected for many possible confounders. Because no major differences were observed after this adjustment, confounding by indication does not seem to be a significant problem. However, residual confounding might still be present, as a result of remaining confounding variables related to the indication for APD or CAPD that were unaccounted for. Because incident patients were included on their original therapy, failure on CAPD could not have been an indication to start APD. Thus, the main indication for APD must have been the preference of the patient or her or his physician, which is difficult to measure, and thus to correct for. A limitation of this study might be the relatively low number of APD patients (13%) in the major analyses. This was mostly due to the inclusion of only incident PD patients. We added an additional analysis 1 yr after the start of dialysis, to increase the number of APD patients. Despite this addition, no difference in survival between the two modalities was found. Another reason for the low number of APD patients was the inclusion period of NECOSAD, which started in 1997 and closed in In these years fewer patients started on APD than nowadays. The results of our study are in line with those of the three small randomized controlled trials (10 12) and two observational studies on this subject (5,9). The main problem with the randomized trials is the size of the cohorts, with a maximum of 50 patients in the largest one (11). In the study from Rodriquez- Carmona et al. (5), more patients were included (53 CAPD and 51 APD patients), although this was still a limited number. This study showed similar results as ours, but the possibility of survival bias cannot be excluded in that study, since inclusion was restricted to PD patients who remained on the same modality for the first 2 yr (5). In contrast to our study, the main analysis in the large cohort of the ANZDATA registry compared patients with at least one episode on APD with patients treated with CAPD only (9). Therefore in this study an effect of previous CAPD therapy cannot be excluded. For this reason we defined our groups at start of dialysis, ruling out any influence of previous dialysis modalities. Furthermore, since APD patients tend to switch to HD, while CAPD patients tend to switch to APD, in our technique failure analysis a switch to any other form of dialysis (including the other PD modality) was considered an event. In the ANZDATA registry switches to another PD modality were not considered as technique failure. Despite the differences in design, our results are in line with those of the ANZDATA study. Our results are in contrast with two large observational studies, which showed a survival benefit for APD (7,8). Both studies included incident PD patients; therefore, they could theoretically have been treated with HD before PD. The Mexican study had the longest follow-up (3 yr), but it was a retrospective single-center study in patients only treated with solutions and machines of one company (8). The registry study from the United States had a short follow-up of one year (7). In both studies adjustment for possible confounders was hampered by the quality of limited data at baseline. Our results imply that APD should not be prescribed to improve survival of incident PD patients, neither the intentionto-treat design, nor the as-treated analyses showed that survival might be better on APD compared with CAPD. Stratification for age, the conditional analysis and the analysis after one year all showed no effect on overall mortality and technique failure. Although not investigated in the present study a switch from CAPD to APD may extend the time on PD. In conclusion, we found no difference in overall mortality and technique failure for APD compared with CAPD in incident dialysis patients. Therefore, the choice to start either one of these therapies should be based on other factors than survival, such as quality of life, patients preference, or available resources. Thus, countries in which prescription of APD is limited because of limited resources do not provide an inferior therapy for their patients. Acknowledgments The nursing staff of the participating hospitals dialysis centers, the trial nurses, and the staff of the NECOSAD trial office are acknowledged for their assistance in the collection and management of data for this study. The members of Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) Study Group include A. J. Apperloo, J. A. Bijlsma, M. Boekhout, W. H. Boer, P. J. M. van der Boog, H. R. Büller, M. van Buren, F. Th. de Charro, C. J. Doorenbos, M. A. van den Dorpel, A. van Es, W. J. Fagel, G.W. Feith, C. W. H. de Fijter, L. A. M. Frenken, W. Grave, J. A. C. A. van Geelen, P. G. G. Gerlag, J. P. M. C. Gorgels, R. M. Huisman, K. J. Jager, K. Jie, W. A. H. Koning-Mulder, M. I. Koolen, T. K. Kremer Hovinga, A. T. J. Lavrijssen, A. J. Luik, J. van der Meulen, K. J. Parlevliet, M. H. M. Raasveld, F. M. van der Sande, M. J. M. Schonck, M. M. J. Schuurmans, C. E. H. Siegert, C. A. Stegeman, P. Stevens,
7 Clin J Am Soc Nephrol 4: , 2009 Similar Survival in APD and CAPD 949 J. G. P. Thijssen, R. M. Valentijn, G. H. Vastenburg, C. A. Verburgh, H. H. Vincent, and P. F. Vos. Disclosures This work was supported by grants from Baxter Healthcare, the Dutch Kidney Foundation and the Dutch National Health Insurance Board. The funding sources were involved in neither the collection, interpretation, and analysis of the data, nor the decision for the writing and submission of this report for publication. References 1. Hiroshige K, Yuu K, Soejima M, Takasugi M, Kuroiwa A: Rapid decline of residual renal function in patients on automated peritoneal dialysis. Perit Dial Int 16: , Hufnagel G, Michel C, Queffeulou G, Skhiri H, Damieri H, Mignon F: The influence of automated peritoneal dialysis on the decrease in residual renal function. Nephrol Dial Transplant 14: , Rodriguez-Carmona A, Fontan MP: Sodium removal in patients undergoing CAPD and automated peritoneal dialysis. Perit Dial Int 22: , Ortega O, Gallar P, Carreno A, Gutierrez M, Rodriguez I, Oliet A, Vigil A, Gimenez E: Peritoneal sodium mass removal in continuous ambulatory peritoneal dialysis and automated peritoneal dialysis: Influence on blood pressure control. Am J Nephrol 21: , Rodriguez-Carmona A, Perez-Fontan M, Garca-Naveiro R, Villaverde P, Peteiro J: Compared time profiles of ultrafiltration, sodium removal, and renal function in incident CAPD and automated peritoneal dialysis patients. Am J Kidney Dis 44: , Westra WM, Kopple JD, Krediet RT, Appell M, Mehrotra R: Dietary protein requirements and dialysate protein losses in chronic peritoneal dialysis patients. Perit Dial Int 27: , Guo A, Mujais S: Patient and technique survival on peritoneal dialysis in the United States: Evaluation in large incident cohorts. Kidney Int 64: S3 12, Sanchez AR, Madonia C, Rascon-Pacheco RA: Improved patient/technique survival and peritonitis rates in patients treated with automated peritoneal dialysis when compared to continuous ambulatory peritoneal dialysis in a Mexican PD center. Kidney Int 73: S76 S80, Badve SV, Hawley CM, McDonald SP, Mudge DW, Rosman JB, Brown FG, Johnson DW: Automated and continuous ambulatory peritoneal dialysis have similar outcomes. Kidney Int 73: , Bro S, Bjorner JB, Tofte-Jensen P, Klem S, Almtoft B, Danielsen H, Meincke M, Friedberg M, Feldt-Rasmussen B: A prospective, randomized multicenter study comparing APD and CAPD treatment. Perit Dial Int 19: , de Fijter CW, Oe LP, Nauta JJ, van der MJ, Verbrugh HA, Verhoef J, Donker AJ: Clinical efficacy and morbidity associated with continuous cyclic compared with continuous ambulatory peritoneal dialysis. Ann Intern Med 120: , Iles-Smith H, Curwell J, Gokal R: Comparative evaluation of CAPD and PD-plus effectiveness. EDTNA ERCA J 25: 27 29, Rabindranath KS, Adams J, Ali TZ, Daly C, Vale L, Macleod AM: Automated vs continuous ambulatory peritoneal dialysis: A systematic review of randomized controlled trials. Nephrol Dial Transplant 22: , Rabindranath KS, Adams J, Ali TZ, Macleod AM, Vale L, Cody J, Wallace SA, Daly C: Continuous ambulatory peritoneal dialysis versus automated peritoneal dialysis for end-stage renal disease. Cochrane Database Syst Rev CD006515, Davies SJ, Russell L, Bryan J, Phillips L, Russell GI: Comorbidity, urea kinetics, and appetite in continuous ambulatory peritoneal dialysis patients: Their interrelationship and prediction of survival. Am J Kidney Dis 26: , van Dijk PC, Jager KJ, de CF, Collart F, Cornet R, Dekker FW, Gronhagen-Riska C, Kramar R, Leivestad T, Simpson K, Briggs JD: Renal replacement therapy in Europe: The results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. Nephrol Dial Transplant 16: , Visser R, Dekker FW, Boeschoten EW, Stevens P, Krediet RT: Reliability of the 7-point subjective global assessment scale in assessing nutritional status of dialysis patients. Adv Perit Dial 15: , Dekker FW, de MR, van Dijk PC, Zoccali C, Jager KJ: Survival analysis: Time-dependent effects and time-varying risk factors. Kidney Int 74: , 2008
A positive effect of AII inhibitors on peritoneal membrane function in long-term PD patients
Nephrol Dial Transplant (2009) 24: 272 277 doi: 10.1093/ndt/gfn421 Advance Access publication 30 July 2008 Original Article A positive effect of AII inhibitors on peritoneal membrane function in long-term
More informationTime trends in initiation and dose of dialysis in end-stage renal disease patients in The Netherlands
Nephrol Dial Transplant (2003) 18: 552 558 Original Article Time trends in initiation and dose of dialysis in end-stage renal disease patients in The Netherlands Fabian Termorshuizen 1, Johanna C. Korevaar
More informationConcern about the decreasing use of peritoneal dialysis
Page 1 of 8 Peritoneal Dialysis International Peritoneal Dialysis International, Vol. 30, pp. doi: 10.3747/pdi.2008.00277 0896-8608/10 $3.00 +.00 Copyright 2010 International Society for Peritoneal Dialysis
More informationThe outcomes of continuous ambulatory and automated peritoneal dialysis are similar
http://www.kidney-international.org & 2009 International Society of Nephrology see commentary on page 12 The outcomes of continuous ambulatory and automated peritoneal dialysis are similar Rajnish Mehrotra
More informationYou can sleep while I dialyze
You can sleep while I dialyze Nocturnal Peritoneal Dialysis Dr. Suneet Singh Medical Director, PD, VGH Division of Nephrology University of British Columbia Acknowledgements Melissa Etheridge You can sleep
More informationMuscle mass depletion and weight loss are associated with increased mortality in hemodialysis patients, independent of body mass index
4 Muscle mass depletion and weight loss are associated with increased mortality in hemodialysis patients, independent of body mass index R. de Mutsert D.C. Grootendorst E.W. Boeschoten R.T. Krediet S.
More informationAutomated peritoneal dialysis (APD) has become
Peritoneal Dialysis International, Vol. 32, pp. 605 611 doi: 10.3747/pdi.2011.00166 0896-8608/12 $3.00 +.00 Copyright 2012 International Society for Peritoneal Dialysis TIME COURSE OF PERITONEAL FUNCTION
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Mode of dialysis at initiation GUIDELINES
Date written: September 2004 Final submission: February 2005 Mode of dialysis at initiation GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationEffect of Peritoneal Dialysis Modality on the 1-Year Rate of Decline of Residual Renal Function
Original Article http://dx.doi.org/10.3349/ymj.2014.55.1.141 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 55(1):141-148, 2014 Effect of Peritoneal Dialysis Modality on the 1-Year Rate of Decline of
More informationSocial support predicts survival in dialysis patients
Nephrol Dial Transplant (2007) 22: 845 850 doi:10.1093/ndt/gfl700 Advance Access publication 12 December 2006 Original Article Social support predicts survival in dialysis patients Melissa S. Y. Thong
More informationThe control of extracellular fluid volume (ECFV) is a
Comparison of Volume Overload with Cycler-Assisted versus Continuous Ambulatory Peritoneal Dialysis Sara N. Davison,* Gian S. Jhangri, Kailash Jindal,* and Neesh Pannu* *Division of Nephrology and Department
More informationThe Effect of Residual Renal Function at the Initiation of Dialysis on Patient Survival
ORIGINAL ARTICLE DOI: 10.3904/kjim.2009.24.1.55 The Effect of Residual Renal Function at the Initiation of Dialysis on Patient Survival Seoung Gu Kim 1 and Nam Ho Kim 2 Department of Internal Medicine,
More information3/21/2017. Solute Clearance and Adequacy Targets in Peritoneal Dialysis. Peritoneal Membrane. Peritoneal Membrane
3/21/2017 Solute Clearance and Adequacy Targets in Peritoneal Dialysis Steven Guest MD Director, Medical Consulting Services Baxter Healthcare Corporation Deerfield, IL, USA Peritoneal Membrane Image courtesy
More informationExcess mortality due to interaction between proteinenergy wasting, inflammation and cardiovascular disease in chronic dialysis patients
7 Excess mortality due to interaction between proteinenergy wasting, inflammation and cardiovascular disease in chronic dialysis patients R. de Mutsert D.C. Grootendorst J. Axelsson E.W. Boeschoten R.T.
More informationAna Paula Bernardo. CHP Hospital de Santo António ICBAS/ Universidade do Porto
Ana Paula Bernardo CHP Hospital de Santo António ICBAS/ Universidade do Porto Clinical relevance of hyperphosphatemia Phosphate handling in dialysis patients Phosphate kinetics in PD peritoneal phosphate
More informationImprovement in Pittsburgh Symptom Score Index After Initiation of Peritoneal Dialysis
Advances in Peritoneal Dialysis, Vol. 24, 2008 Matthew J. Novak, 1 Heena Sheth, 2 Filitsa H. Bender, 1 Linda Fried, 1,3 Beth Piraino 1 Improvement in Pittsburgh Symptom Score Index After Initiation of
More informationEffect of previously failed kidney transplantation on peritoneal dialysis outcomes in the Australian and New Zealand patient populations
NDT Advance Access published November 9, 2005 Nephrol Dial Transplant (2005) 1 of 8 doi:10.1093/ndt/gfi248 Original Article Effect of previously failed kidney transplantation on peritoneal dialysis outcomes
More informationThe Association between Peritoneal Dialysis Modality and Peritonitis
Article The Association between Peritoneal Dialysis Modality and Peritonitis Patrick G. Lan, David W. Johnson, Stephen P. McDonald, Neil Boudville, Monique Borlace, Sunil V. Badve, Kamal Sud, and Philip
More informationPredictive Factors for Withdrawal from Peritoneal Dialysis: A Retrospective Cohort Study at Two Centers in Japan
Advances in Peritoneal Dialysis, Vol. 33, 2017 Yasuhiro Taki, 1 Tsutomu Sakurada, 2 Kenichiro Koitabashi, 2 Naohiko Imai, 1 Yugo Shibagaki 2 Predictive Factors for Withdrawal from Peritoneal Dialysis:
More informationPeritoneal Dialysis Adequacy: Not Just Small- Solute Clearance
Advances in Peritoneal Dialysis, Vol. 24, 2008 Rajesh Yalavarthy, Isaac Teitelbaum Peritoneal Dialysis Adequacy: Not Just Small- Solute Clearance Two indices of small-solute clearance, Kt/V urea and creatinine
More informationJ Am Soc Nephrol 15: , 2004
J Am Soc Nephrol 15: 1061 1070, 2004 Relative Contribution of Residual Renal Function and Different Measures of Adequacy to Survival in Hemodialysis Patients: An analysis of the Netherlands Cooperative
More informationTHERAPEUTIC INTERVENTIONS TO PRESERVE RESIDUAL KIDNEY FUNCTION. Rajnish Mehrotra Harborview Medical Center University of Washington, Seattle
THERAPEUTIC INTERVENTIONS TO PRESERVE RESIDUAL KIDNEY FUNCTION Rajnish Mehrotra Harborview Medical Center University of Washington, Seattle 1 2 Outline of Presentation Refinements in our understanding
More informationPatient and technique survival on peritoneal dialysis in patients with failed renal allograft: A case control study
http://www.kidney-international.org & 2006 International Society of Nephrology Patient and technique survival on peritoneal dialysis in patients with failed renal allograft: A case control study S Mujais
More informationAn Automated Peritoneal Dialysis regimen is not detrimental to Residual Renal Function
ORIGINAL ARTICLE Port J Nephrol Hypert 2016; 30 4 : 277 284 Advance Access publication 25 November 2016 An Automated Peritoneal Dialysis regimen is not detrimental to Residual Renal Function Cristina Candido
More informationWHEN (AND WHEN NOT) TO START DIALYSIS. Shahid Chandna, Ken Farrington
WHEN (AND WHEN NOT) TO START DIALYSIS Shahid Chandna, Ken Farrington Changing Perspectives Beta blockers 1980s Contraindicated in heart failure Now mainstay of therapy HRT 1990s must Now only if you have
More informationOriginal article. Introduction. Jong Soon Jang, M.D. Soon Kil Kwon, M.D. Hye-Young Kim, M.D.
Original article ISSN 1738-5997 (Print) ISSN 2092-9935 (Online) Electrolyte Blood Press 9:16-22, 2011 doi: 10.5049/EBP.2011.9.1.16 Comparison of Blood Pressure Control and Left Ventricular Hypertrophy
More informationPredictors of Peritonitis in Patients on Peritoneal Dialysis: Results of a Large, Prospective Canadian Database
Predictors of Peritonitis in Patients on Peritoneal Dialysis: Results of a Large, Prospective Canadian Database Sharon J. Nessim,* Joanne M. Bargman, Peter C. Austin, Rosane Nisenbaum, and Sarbjit V. Jassal
More informationChanges in parathyroid hormone and body mass index and the association with mortality in dialysis patients
Nephrol Dial Transplant (2011) 26: 1340 1346 doi: 10.1093/ndt/gfq541 Advance Access publication 14 September 2010 Changes in parathyroid hormone and body mass index and the association with mortality in
More informationMETABOLISM AND NUTRITION WITH PD OBESITY. Rajnish Mehrotra Harborview Medical Center University of Washington, Seattle
METABOLISM AND NUTRITION WITH PD OBESITY Rajnish Mehrotra Harborview Medical Center University of Washington, Seattle 1 Body Size in Patients New to Dialysis United States Body Mass Index, kg/m2 33 31
More informationAssociation between causes of peritoneal dialysis technique failure and all-cause mortality
www.nature.com/scientificreports Received: 27 September 2017 Accepted: 21 February 2018 Published: xx xx xxxx OPEN Association between causes of peritoneal dialysis technique failure and all-cause mortality
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Monitoring patients on peritoneal dialysis GUIDELINES
Date written: August 2004 Final submission: July 2005 Monitoring patients on peritoneal dialysis GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR CLINICAL CARE (Suggestions
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Level of renal function at which to initiate dialysis GUIDELINES
Level of renal function at which to initiate dialysis Date written: September 2004 Final submission: February 2005 GUIDELINES No recommendations possible based on Level I or II evidence SUGGESTIONS FOR
More informationContinuous Ambulatory Peritoneal Dialysis and Automated Peritoneal Dialysis: What, Who, Why, and How? Review and Case Study
Advances in Peritoneal Dialysis, Vol. 33, 2017 Kunal Malhotra, Ramesh Khanna Continuous Ambulatory Peritoneal Dialysis and Automated Peritoneal Dialysis: What, Who, Why, and How? Review and Case Study
More informationHyperphosphatemia is a strong predictor of overall
Peritoneal Phosphate Clearance is Influenced by Peritoneal Dialysis Modality, Independent of Peritoneal Transport Characteristics Sunil V. Badve,* Deborah L. Zimmerman,* Greg A. Knoll, * Kevin D. Burns,*
More informationObjectives. Peritoneal Dialysis vs. Hemodialysis 02/27/2018. Peritoneal Dialysis Prescription and Adequacy Monitoring
Peritoneal Dialysis Prescription and Adequacy Monitoring Christine B. Sethna, MD, EdM Division Director, Pediatric Nephrology Cohen Children s Medical Center Associate Professor Hofstra Northwell School
More informationFrom Peritoneal Dialysis to Hemodialysis How could we improve the transition? Th Lobbedez CHU de Caen Self Dialysis Meeting 22 May 2014
From Peritoneal Dialysis to Hemodialysis How could we improve the transition? Th Lobbedez CHU de Caen Self Dialysis Meeting 22 May 2014 Deux grands principes concernant la DP La dialyse péritonéale doit
More informationHome Hemodialysis or Transplantation of the Treatment of Choice for Elderly?
Home Hemodialysis or Transplantation of the Treatment of Choice for Elderly? Miklos Z Molnar, MD, PhD, FEBTM, FERA, FASN Associate Professor of Medicine Division of Nephrology, Department of Medicine University
More informationFIRST RENAL REPLACEMENT
FIRST RENAL REPLACEMENT THERAPY SELECTION IN DIABETIC PATIENTS Dr Cécile Couchoud (REIN registry, France) Davide Bolignano (ERBP, Italy) European Renal Best Practice Prof. Wim Van Biesen Chairman of ERBP
More informationChapter 12 PERITONEAL DIALYSIS
Chapter 12 PERITONEAL DIALYSIS B. Sunita A/P V. Bavanandan Anita Bhajan Manocha Lily Binti Mushahar Mohamad Zaimi Bin Abdul Wahab Sudhaharan Sivathasan PERITONEAL DIALYSIS 22nd Report of the SECTION 12.1:
More informationEarly Estimation of High Peritoneal Permeability Can Predict Poor Prognosis for Technique Survival in Patients on Peritoneal Dialysis
Advances in Peritoneal Dialysis, Vol. 22, 2006 Hidetomo Nakamoto, 1,2 Hirokazu Imai, 2 Hideki Kawanishi, 2 Masahiko Nakamoto, 2 Jun Minakuchi, 2 Shinichi Kumon, 2 Syuichi Watanabe, 2 Yoshhiko Shiohira,
More informationPART ONE. Peritoneal Kinetics and Anatomy
PART ONE Peritoneal Kinetics and Anatomy Advances in Peritoneal Dialysis, Vol. 22, 2006 Paul A. Fein, Irfan Fazil, Muhammad A. Rafiq, Teresa Schloth, Betty Matza, Jyotiprakas Chattopadhyay, Morrell M.
More informationPredictors of Patient Survival in Continuous Ambulatory Peritoneal Dialysis 10-Year Experience in 2 Major Centers in Tehran
Dialysis Predictors of Patient Survival in Continuous Ambulatory Peritoneal Dialysis 10-Year Experience in 2 Major Centers in Tehran Monir Sadat Hakemi, 1 Mehdi Golbabaei, 2 Amirahmad Nassiri, 3 Mandana
More informationAdvances in Peritoneal Dialysis, Vol. 29, 2013
Advances in Peritoneal Dialysis, Vol. 29, 2013 Takeyuki Hiramatsu, 1 Takahiro Hayasaki, 1 Akinori Hobo, 1 Shinji Furuta, 1 Koki Kabu, 2 Yukio Tonozuka, 2 Yoshiyasu Iida 1 Icodextrin Eliminates Phosphate
More informationEarly Initiation of Dialysis Fails to Prolong Survival in Patients with End-Stage Renal Failure
J Am Soc Nephrol 13: 2125 2132, 2002 Early Initiation of Dialysis Fails to Prolong Survival in Patients with End-Stage Renal Failure JAMIE P. TRAYNOR,* KEITH SIMPSON,* COLIN C. GEDDES, CHRISTOPHER J. DEIGHAN,*
More informationCHAPTER 6 PERITONEAL DIALYSIS. Neil Boudville. Hannah Dent. Stephen McDonald. Kylie Hurst. Philip Clayton Annual Report - 36th Edition
CHAPTER 6 Neil Boudville Hannah Dent Stephen McDonald Kylie Hurst Philip Clayton 213 Annual Report - 36th Edition ANZDATA Registry 213 Report STOCK AND FLOW AUSTRALIA Peritoneal dialysis was used to treat
More informationEconomic evaluation of end stage renal disease treatment Ardine de Wit G, Ramsteijn P G, de Charro F T
Economic evaluation of end stage renal disease treatment Ardine de Wit G, Ramsteijn P G, de Charro F T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion
More informationPeritoneal dialysis in the US: Evaluation of outcomes in contemporary cohorts
http://www.kidney-international.org & 2006 International Society of Nephrology Peritoneal dialysis in the US: Evaluation of outcomes in contemporary cohorts S Mujais 1 and K Story 1 1 Renal Division, Baxter
More informationCorrespondence to: L. Cuppari, Rua Pedro de Toledo, 282, São Paulo, SP, Brasil Fax:
1116 Brazilian Journal of Medical and Biological Research (2008) 41: 1116-1122 ISSN 0100-879X Nutritional status and body composition after 6 months of patients switching from continuous ambulatorial peritoneal
More informationBrief communication (Original)
Asian Biomedicine Vol. 8 No. 1 February 2014; 67-73 DOI: 10.5372/1905-7415.0801.263 Brief communication (Original) Long-term clinical effects of treatment by daytime ambulatory peritoneal dialysis with
More informationOptions in Renal Replacement Therapy: When, whom, which? Prof Dr. Serhan Tuğlular Marmara University Medical School Division of Nephrology
Options in Renal Replacement Therapy: When, whom, which? Prof Dr. Serhan Tuğlular Marmara University Medical School Division of Nephrology CKD Classification Stage Description GFR (ml/min/1.73.m2) 1 Kidney
More informationNephrology. Renal Replacement in End-Stage Renal Disease Patients over 75 Years Old. ABC Fax
American Journal of Nephrology Original Article: Basic Sciences Am J Nephrol 2003;23:7 77 DOI: 0.59/000068040 Received: July 23, 2002 Accepted: October 2, 2002 Renal Replacement in End-Stage Renal Disease
More informationChapter 2 Peritoneal Equilibration Testing and Application
Chapter 2 Peritoneal Equilibration Testing and Application Francisco J. Cano Case Presentation FW, a recently diagnosed patient with CKD Stage 5, is a 6-year-old boy who has been recommended to initiate
More informationState Profile for FY 2018 for Dialysis Patients and Facilities - STATE SAMPLE
Dear State Surveyor: State Profile for FY 2018 for Dialysis Patients and Facilities - STATE SAMPLE This report is designed to provide a comparative summary of treatment patterns and patient outcomes for
More informationVariable Included. Excluded. Included. Excluded
Table S1. Baseline characteristics of patients included in the analysis and those excluded patients because of missing baseline serumj bicarbonate levels, stratified by dialysis modality. Variable HD patients
More informationAdvances in Peritoneal Dialysis, Vol. 23, 2007
Advances in Peritoneal Dialysis, Vol. 23, 2007 Antonios H. Tzamaloukas, 1,2 Aideloje Onime, 1,2 Dominic S.C. Raj, 2 Glen H. Murata, 1 Dorothy J. VanderJagt, 3 Karen S. Servilla 1,2 Computation of the Dose
More informationMeeting the Guidelines for End-of-Life Care
Advances in Peritoneal Dialysis, Vol. 22, 2006 Gillian Brunier, David M.J. Naimark, Michelle A. Hladunewich Meeting the Guidelines for End-of-Life Care The number of patients initiating dialysis in most
More information2008 Dialysis Facility Report
iii Purpose of the Report Enclosed is the (DFR) for this facility, based on data from the Centers for Medicare & Medicaid Services (CMS). This DFR includes data specific to provider number(s): 102844 These
More informationPeritoneal dialysis as a treatment option in autosomal dominant polycystic kidney disease
Int Urol Nephrol (2015) 47:1739 1744 DOI 10.1007/s11255-015-1087-9 NEPHROLOGY - ORIGINAL ARTICLE Peritoneal dialysis as a treatment option in autosomal dominant polycystic kidney disease Magdalena Jankowska
More informationHaemodiafiltration - the case against. Prof Peter G Kerr Professor/Director of Nephrology Monash Health
Haemodiafiltration - the case against Prof Peter G Kerr Professor/Director of Nephrology Monash Health Know your opposition.. Haemodiafiltration NB: pre or post-dilution What is HDF how is it different
More informationKrediet slide di 18
1 di 18 Assessment of fluid status in PD patients Raymond T. Krediet, Amsterdam, Netherlands Chairs:Walther H. Boer, Utrecht, The Netherlands F. Fevzi Ersoy, Antalya, Turkey Prof. Raymond T. Krediet DDivision
More informationAJNT. Original Article
. 2012 May;5(2):81-6 Original Article AJNT Reaching Target Hemoglobin Level and Having a Functioning Arteriovenous Fistula Significantly Improve One Year Survival in Twice Weekly Hemodialysis Sarra Elamin
More informationWhen to start dialysis?
Nephrol Dial Transplant (2006) 21 [Suppl 2]: ii20 ii24 doi:10.1093/ndt/gfl139 Original Article When to start dialysis? C. E. Douma 1 and W. Smit 2 1 Department of Nephrology, VU University Medical Center,
More informationIntravenous Iron Does Not Affect the Rate of Decline of Residual Renal Function in Patients on Peritoneal Dialysis
Advances in Peritoneal Dialysis, Vol. 22, 2006 Hemal Shah, Ashutosh Shukla, Abirami Krishnan, Theodore Pliakogiannis, Mufazzal Ahmad, Joanne M. Bargman, Dimitrios G. Oreopoulos Intravenous Iron Does Not
More informationEffect of Kt/V on survival and clinical outcome in CAPD patients in a randomized prospective study
Kidney International, Vol. 64 (2003), pp. 649 656 DIALYSIS TRANSPLANTATION Effect of Kt/V on survival and clinical outcome in CAPD patients in a randomized prospective study WAI-KEI LO, YIU-WING HO, CHUN-SANG
More informationDiagnostic methods 2: receiver operating characteristic (ROC) curves
abc of epidemiology http://www.kidney-international.org & 29 International Society of Nephrology Diagnostic methods 2: receiver operating characteristic (ROC) curves Giovanni Tripepi 1, Kitty J. Jager
More informationWhy NxStage? 4th self-care dialysis symposium 6th & 7th June 2018 Brussels. Page 1
Why NxStage? 4th self-care dialysis symposium 6th & 7th June 2018 Brussels Page 1 Are you prepared? 4.1% Annual increase 1 in European dialysis patients Reference: 1. 2017 USRDS Annual Data Report Reference
More informationTRENDS IN RENAL REPLACEMENT THERAPY IN BOSNIA AND HERZEGOVINA
& TRENDS IN RENAL REPLACEMENT THERAPY IN BOSNIA AND HERZEGOVINA 2002-2008 Halima Resić* 1, Enisa Mešić 2 1 Clinic for Hemodialysis, University of Sarajevo Clinics Centre, Bolnička 25, 71000 Sarajevo, Bosnia
More informationI. CLINICAL PRACTICE GUIDELINES FOR PERITONEAL DIALYSIS ADEQUACY
I. CLINICAL PRACTICE GUIDELINES FOR PERITONEAL DIALYSIS ADEQUACY GUIDELINE 1. INITIATION OF DIALYSIS 1.1 Preparation for kidney failure: Patients who reach chronic kidney disease (CKD) stage 4 (estimated
More informationComparison of mortality with home hemodialysis and center hemodialysis: A national study
Kidney International, Vol. 49 (1996), pp. 1464 1470 Comparison of mortality with home hemodialysis and center hemodialysis: A national study JOHN D. WooDs, FRIEDRICH K. PORT, DAVID STANNARD, CHRISTOPHER
More informationChapter 2 End-Stage Renal Disease: Scope and Trends
Chapter 2 End-Stage Renal Disease: Scope and Trends Chapter 2 End-Stage Renal Disease: Scope and Trends END-STAGE RENAL DISEASE DEFINED The primary functions of the kidney are to remove waste products
More informationGeographic and Educational Factors and Risk of the First Peritonitis Episode in Brazilian Peritoneal Dialysis Study (BRAZPD) Patients
Article Geographic and Educational Factors and Risk of the First Peritonitis Episode in Brazilian Peritoneal Dialysis Study (BRAZPD) Patients Luis C. Martin,* Jacqueline C.T. Caramori,* Natalia Fernandes,
More informationEffect of Initial PET Status on Clinical Course in Peritoneal Dialysis Patients
BANTAO Journal 2015; 13(1): 14-19; doi:10.1515/bj-2015-0004 BJ BANTAO Journal Original article Effect of Initial PET Status on Clinical Course in Peritoneal Dialysis Patients Tamer Sakaci¹, Yener Koc²,
More information2011 Dialysis Facility Report
Purpose of the Report 2011 Dialysis Facility Report Enclosed is the 2011 Dialysis Facility Report (DFR) for your facility, based on data from the Centers for Medicare & Medicaid Services (CMS). This DFR
More informationEffects of a Nationwide Predialysis Educational Program on Modality Choice, Vascular Access, and Patient Outcomes
Original Investigation Effects of a Nationwide Predialysis Educational Program on Modality Choice, Vascular Access, and Patient Outcomes Eduardo Lacson Jr, MD, MPH, Weiling Wang, MS, Cari DeVries, Keith
More informationAssociation Between Residual Kidney Function and Visit-to-Visit Blood Pressure Variability in Peritoneal Dialysis Patients
Advances in Peritoneal Dialysis, Vol. 31, 2015 Kei Yokota, 1,2 Tsutomu Sakurada, 1 Kenichiro Koitabashi, 1 Yugo Shibagaki, 1 Kazuomi Kario, 2 Kenjiro Kimura 3 Association Between Residual Kidney Function
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients
More informationThe peritoneal equilibration test (PET) was developed THE SHORT PET IN PEDIATRICS. Bradley A. Warady and Janelle Jennings
Peritoneal Dialysis International, Vol. 27, pp. 441 445 Printed in Canada. All rights reserved. 0896-8608/07 $3.00 +.00 Copyright 2007 International Society for Peritoneal Dialysis THE SHORT PET IN PEDIATRICS
More informationCHAPTER 6 PERITONEAL DIALYSIS. Fiona Brown Aarti Gulyani Stephen McDonald Kylie Hurst Annual Report 35th Edition
CHAPTER 6 PERITONEAL DIALYSIS Fiona Brown Aarti Gulyani Stephen McDonald Kylie Hurst 212 Annual Report 35th Edition PERITONEAL DIALYSIS ANZDATA Registry 212 Report STOCK AND FLOW AUSTRALIA Peritoneal dialysis
More informationOutcomes of chronic dialysis in Korean children with respect to survival rates and causes of death
Original article Korean J Pediatr 2014;57(3):135-139 pissn 1738-1061 eissn 2092-7258 Korean J Pediatr Outcomes of chronic dialysis in Korean children with respect to survival rates and causes of death
More informationPART FOUR. Metabolism and Nutrition
PART FOUR Metabolism and Nutrition Advances in Peritoneal Dialysis, Vol. 22, 2006 Costas Fourtounas, Eirini Savidaki, Marilena Roumelioti, Periklis Dousdampanis, Andreas Hardalias, Pantelitsa Kalliakmani,
More informationDe Novo Hypokalemia in Incident Peritoneal Dialysis
Original investigation 73 1) De Novo Hypokalemia in Incident Peritoneal Dialysis Patients: A 1-Year Observational Study Ji Yong Jung, M.D., Jae Hyun Chang, M.D., Hyun Hee Lee, M.D., Wookyung Chung, M.D.
More information2011 Dialysis Facility Report SAMPLE Dialysis Facility State: XX Network: 99 CCN: SAMPLE Dialysis Facility Report SAMPLE
Purpose of the Report Enclosed is the (DFR) for your facility, based on data from the Centers for Medicare & Medicaid Services (CMS). This DFR includes data specific to CCN(s): 999999 These data could
More information2010 Dialysis Facility Report
Purpose of the Report 2010 Dialysis Facility Report Enclosed is the 2010 Dialysis Facility Report (DFR) for this facility, based on data from the Centers for Medicare & Medicaid Services (CMS). This DFR
More informationAcceptance onto dialysis guidelines: St George Hospital
Acceptance onto dialysis guidelines: St George Hospital The following information is a guideline to support clinicians in decision making regarding acceptance onto dialysis. A review of international guidelines
More information2016 Annual Dialysis Conference Michelle Hofmann RN, BSN, CNN Renal Clinical Educator - Home
Fluid Management 2016 Annual Dialysis Conference Michelle Hofmann RN, BSN, CNN Renal Clinical Educator - Home Objectives Define euvolemia Determine factors which contribute to fluid imbalance Discuss strategies
More informationVolume Management 2/25/2017. Disclosures statement: Objectives. To discuss evaluation of hypervolemia in peritoneal dialysis patients
Volume Management Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 14, 2017 Disclosures statement: Consultant: Allena, Becker Professional Education Grant
More informationHow to preserve residual renal function in patients with chronic kidney disease and on dialysis?
Nephrol Dial Transplant (2006) 21 [Suppl 2]: ii42 ii46 doi:10.1093/ndt/gfl137 Original Article How to preserve residual renal function in patients with chronic kidney disease and on dialysis? Raymond T.
More informationMalnutrition and inflammation in peritoneal dialysis patients
Kidney International, Vol. 64, Supplement 87 (2003), pp. S87 S91 Malnutrition and inflammation in peritoneal dialysis patients PAUL A. FEIN, NEAL MITTMAN, RAJDEEP GADH, JYOTIPRAKAS CHATTOPADHYAY, DANIEL
More informationLinear and logistic regression analysis
abc of epidemiology http://www.kidney-international.org & 008 International Society of Nephrology Linear and logistic regression analysis G Tripepi, KJ Jager, FW Dekker, and C Zoccali CNR-IBIM, Clinical
More informationIncreased peritoneal dialysis utilization and improved patient survival over a 20-year period: data from a Portuguese Peritoneal Dialysis Unit
ORIGINAL ARTICLE Port J Nephrol Hypert 2016; 30(2): 113-120 Advance Access publication 30 January 2016 Increased peritoneal dialysis utilization and improved patient survival over a 20-year period: data
More informationNarender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York
Narender Goel et al. Middletown Medical PC, Montefiore Medical Center & Albert Einstein College of Medicine, New York 4th International Conference on Nephrology & Therapeutics September 14, 2015 Baltimore,
More informationType of arteriovenous vascular access and association with patency and mortality
Ocak et al. BMC Nephrology 2013, 14:79 RESEARCH ARTICLE Type of arteriovenous vascular access and association with patency and mortality Gürbey Ocak 1, Joris I Rotmans 2, Carla Y Vossen 1,3, Frits R Rosendaal
More informationCHAPTER 6 PERITONEAL DIALYSIS
CHAPTER 6 PERITONEAL DIALYSIS Fiona Brown Aarti Gulyani Hannah Dent Kylie Hurst Stephen McDonald PERITONEAL DIALYSIS ANZDATA Registry 11 Report STOCK AND FLOW AUSTRALIA Peritoneal dialysis was used to
More informationThe EQUAL study: a European study in chronic kidney disease stage 4 patients
Nephrol Dial Transplant (2012) 27 (Supple 3): iii27 iii31 doi: 10.1093/ndt/gfs277 Advance Access publication 4 July 2012 Editorial Review The EQUAL study: a European study in chronic kidney disease stage
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 2: Identification and Care of Patients With CKD Over half of patients from the Medicare 5 percent sample have either a diagnosis of chronic kidney disease
More informationMulticenter Registry Analysis of Center Characteristics Associated with Technique Failure in Patients on Incident Peritoneal Dialysis
CJASN epress. Published on June 21, 2017 as doi: 10.2215/CJN.12321216 Article Multicenter Registry Analysis of Center Characteristics Associated with Technique Failure in Patients on Incident Peritoneal
More informationSELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
More information2015 Children's Mercy Hospitals and Clinics. All Rights Reserved.
Growth van Stralen KJ, et al., Kidney Int, 2014 Blood Pressure Management van Stralen KJ, et al., Kidney Int, 2014 Sodium Losses on PD Infants might need higher UF rate per BSA as compared to adults to
More informationPRESERVATION OF RESIDUAL RENAL FUNCTION IN DIALYSIS PATIENTS: EFFECTS OF DIALYSIS-TECHNIQUE RELATED FACTORS
Peritoneal Dialysis International, Vol. 21, pp. 52 57 Printed in Canada. All rights reserved. 0896-8608/00 $3.00 +.00 Copyright 2001 International Society for Peritoneal Dialysis PRESERVATION OF RESIDUAL
More informationThe greatest benefit of peritoneal dialysis (PD) is the
Peritoneal Dialysis International, Vol. 26, pp. 150 154 Printed in Canada. All rights reserved. 0896-8608/06 $3.00 +.00 Copyright 2006 International Society for Peritoneal Dialysis COMBINATION THERAPY
More information